JP2009521521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009521521A5 JP2009521521A5 JP2008548072A JP2008548072A JP2009521521A5 JP 2009521521 A5 JP2009521521 A5 JP 2009521521A5 JP 2008548072 A JP2008548072 A JP 2008548072A JP 2008548072 A JP2008548072 A JP 2008548072A JP 2009521521 A5 JP2009521521 A5 JP 2009521521A5
- Authority
- JP
- Japan
- Prior art keywords
- buffer
- composition
- kit
- solution
- thiol protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 21
- 239000000872 buffer Substances 0.000 claims 17
- 239000000243 solution Substances 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 15
- 101710097834 Thiol protease Proteins 0.000 claims 14
- 239000011780 sodium chloride Substances 0.000 claims 13
- 239000012141 concentrate Substances 0.000 claims 7
- 239000000463 material Substances 0.000 claims 7
- 230000003204 osmotic effect Effects 0.000 claims 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 230000002797 proteolythic effect Effects 0.000 claims 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 239000007987 MES buffer Substances 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 239000003638 chemical reducing agent Substances 0.000 claims 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 4
- 108090000526 Papain Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 239000008351 acetate buffer Substances 0.000 claims 3
- 239000002738 chelating agent Substances 0.000 claims 3
- 238000007865 diluting Methods 0.000 claims 3
- 235000019834 papain Nutrition 0.000 claims 3
- 229940055729 papain Drugs 0.000 claims 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- 108010024636 Glutathione Proteins 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000007993 MOPS buffer Substances 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 2
- 239000007979 citrate buffer Substances 0.000 claims 2
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims 2
- 229940099500 cystamine Drugs 0.000 claims 2
- 229960002433 cysteine Drugs 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- 229960001305 cysteine hydrochloride Drugs 0.000 claims 2
- 238000001804 debridement Methods 0.000 claims 2
- 229960001484 edetic acid Drugs 0.000 claims 2
- YUPQOCKHBKYZMN-UHFFFAOYSA-N ethylaminomethanetriol Chemical group CCNC(O)(O)O YUPQOCKHBKYZMN-UHFFFAOYSA-N 0.000 claims 2
- 229960003180 glutathione Drugs 0.000 claims 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 206010040882 skin lesion Diseases 0.000 claims 2
- 231100000444 skin lesion Toxicity 0.000 claims 2
- 239000008362 succinate buffer Substances 0.000 claims 2
- -1 thiol compound Chemical class 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 claims 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000013618 particulate matter Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75340005P | 2005-12-27 | 2005-12-27 | |
| US60/753,400 | 2005-12-27 | ||
| PCT/IL2006/001492 WO2007074454A2 (en) | 2005-12-27 | 2006-12-27 | Stable enzymatic preparations and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009521521A JP2009521521A (ja) | 2009-06-04 |
| JP2009521521A5 true JP2009521521A5 (https=) | 2010-02-12 |
| JP5435955B2 JP5435955B2 (ja) | 2014-03-05 |
Family
ID=37943776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008548072A Expired - Fee Related JP5435955B2 (ja) | 2005-12-27 | 2006-12-27 | 安定な酵素製剤及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8197808B2 (https=) |
| EP (1) | EP1965763B1 (https=) |
| JP (1) | JP5435955B2 (https=) |
| DK (1) | DK1965763T3 (https=) |
| ES (1) | ES2763724T3 (https=) |
| WO (1) | WO2007074454A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US8197808B2 (en) | 2005-12-27 | 2012-06-12 | Ramot At Tel-Aviv University Ltd. | Stable enzymatic preparations and methods of use thereof |
| JP5213137B2 (ja) * | 2006-12-06 | 2013-06-19 | コーネル リサーチ ファウンデーション， インコーポレイテッド | 中程度の持続時間の神経筋遮断剤およびそのアンタゴニスト |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| ES2759373T3 (es) * | 2008-06-12 | 2020-05-08 | Medtronic Xomed Inc | Producto para el tratamiento de heridas crónicas con un sistema extracelular de solvatación de sustancias poliméricas |
| US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| EP2318035B1 (en) | 2008-07-01 | 2019-06-12 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| CA2747611C (en) | 2009-01-06 | 2019-09-17 | Curemark Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
| WO2010080835A1 (en) | 2009-01-06 | 2010-07-15 | Curemark Llc | Compositions and methods for the treatment or the prevention oral infections by e. coli |
| EP2226382A1 (en) | 2009-03-03 | 2010-09-08 | B.R.A.I.N. Biotechnology Research and Information Network AG | Protease for wound conditioning and skin care |
| WO2010107488A1 (en) | 2009-03-17 | 2010-09-23 | Cornell University | Reversible nondepolarizing neuromuscular blockade agents and methods for their use |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| CN102573794B (zh) * | 2009-08-19 | 2017-03-15 | 康奈尔大学 | 供生理注射用的半胱氨酸 |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| WO2012030653A2 (en) | 2010-08-29 | 2012-03-08 | Vascode Technologies Ltd. | A system and methods for multi-tasking in a clientless mobile phone |
| JP5976100B2 (ja) | 2011-04-21 | 2016-08-23 | キュアマーク リミテッド ライアビリティ カンパニー | 神経精神障害の処置のための化合物 |
| WO2013032745A1 (en) | 2011-08-31 | 2013-03-07 | Kci Licensing, Inc. | Reduced-pressure treatment and debridement systems and methods |
| CN104220088A (zh) * | 2012-02-02 | 2014-12-17 | 柯尔朗恩有限责任公司 | 酶组合物及其用于创伤愈合的用途 |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| US11364286B2 (en) * | 2015-10-14 | 2022-06-21 | Newsouth Innovations Pty Limited | Compositions and methods for the treatment of diseases involving mucin |
| RU2732224C9 (ru) * | 2016-01-31 | 2021-06-18 | Медивунд Лтд. | Раноочищающая композиция для лечения ран |
| WO2017183018A1 (en) * | 2016-04-18 | 2017-10-26 | Mediwound Ltd | Methods of debridement of chronic wounds |
| US12226464B2 (en) | 2017-04-10 | 2025-02-18 | Curemark, Llc | Compositions for treating addiction |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| CA3199921A1 (en) * | 2020-11-25 | 2022-06-02 | Steven M. Hernandez | Scar treatment composition |
| CN115998690B (zh) * | 2022-11-10 | 2024-07-26 | 上海泰昶生物技术有限公司 | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB913203A (en) | 1958-12-30 | 1962-12-19 | Swift & Co | Enzyme formulations for the production of tenderized meat |
| US3539451A (en) | 1968-05-31 | 1970-11-10 | Castle & Cooke | Production of reversibly inactivated papain and ficin |
| US4307081A (en) | 1974-01-08 | 1981-12-22 | Gerold K. V. Klein | Enzyme mixture |
| US4715899A (en) * | 1982-10-21 | 1987-12-29 | Subir Chanda | Liquid cleaner containing inactivated protease for protein soiled contact lenses |
| JPH0449299A (ja) * | 1990-06-14 | 1992-02-18 | Tosoh Corp | 免疫グロブリンフラグメントの精製法 |
| DE4026591B4 (de) | 1990-08-23 | 2005-08-25 | Pleva Gmbh | Vorrichtung zur Bestimmung der Beladung von Luft mit Dämpfen |
| JP2665639B2 (ja) * | 1992-01-09 | 1997-10-22 | テーオー食品株式会社 | 安定化されたチオール蛋白分解酵素を含む焼き肉のタレ |
| US7364565B2 (en) * | 2001-07-27 | 2008-04-29 | Ramot At Tel Aviv University Ltd. | Controlled enzymatic removal and retrieval of cells |
| MXPA04004479A (es) * | 2001-11-13 | 2004-08-11 | Procter & Gamble | Composiciones topicas que contienen enzimas estabilizadas con inhibidores. |
| US6692726B1 (en) * | 2003-02-11 | 2004-02-17 | Colgate Palmolive Company | Enzyme containing oral composition having enhanced stability |
| ATE429897T1 (de) * | 2003-10-10 | 2009-05-15 | Cosmedical Aps | Haarwuchshemmung |
| US8197808B2 (en) | 2005-12-27 | 2012-06-12 | Ramot At Tel-Aviv University Ltd. | Stable enzymatic preparations and methods of use thereof |
-
2006
- 2006-12-27 US US12/087,108 patent/US8197808B2/en not_active Expired - Fee Related
- 2006-12-27 WO PCT/IL2006/001492 patent/WO2007074454A2/en not_active Ceased
- 2006-12-27 JP JP2008548072A patent/JP5435955B2/ja not_active Expired - Fee Related
- 2006-12-27 ES ES06821673T patent/ES2763724T3/es active Active
- 2006-12-27 DK DK06821673.8T patent/DK1965763T3/da active
- 2006-12-27 EP EP06821673.8A patent/EP1965763B1/en not_active Not-in-force
-
2012
- 2012-01-16 US US13/350,846 patent/US8337837B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009521521A5 (https=) | ||
| Moore et al. | Mechanisms of gastrointestinal ischemia‐reperfusion injury and potential therapeutic interventions: a review and its implications in the horse | |
| ES2633574T3 (es) | Formulaciones de antagonistas de VEGF | |
| US7713929B2 (en) | Rapid acting and long acting insulin combination formulations | |
| Perazella et al. | Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy | |
| US7718609B2 (en) | Rapid acting and long acting insulin combination formulations | |
| ES2709103T3 (es) | Métodos para conservar órganos y tejidos | |
| Lieberman et al. | Inhibitors and activators of leukocytic proteases in purulent sputum: Digestion of human lung and inhibition by alpha1-antitrypsin | |
| JP2024001364A5 (https=) | ||
| Napolitano et al. | Nonventilatory strategies for patients with life-threatening 2009 H1N1 influenza and severe respiratory failure | |
| CA2275890A1 (en) | Stable liquid interferon formulations | |
| JP2010529018A5 (ja) | 医薬組成物、および医薬錠剤 | |
| TWI751379B (zh) | 用於遞送胜肽之藥物組合物 | |
| US20100239663A1 (en) | Composition for foodstuff for binding acetaldehyde | |
| ATE506071T1 (de) | Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa) | |
| JP2005529847A5 (https=) | ||
| Dasta et al. | Acetylcysteine as a cytoprotective antioxidant in patients with severe sepsis: potential new use for an old drug | |
| NZ593190A (en) | Factor viii formulations | |
| JP2025163108A5 (https=) | ||
| Orce et al. | Inhibition of short-circuit current in toad urinary bladder by inhibitors of glandular kallikrein | |
| RU2011122629A (ru) | Водная композиция, содержащая фолликулостимулирующий гормон | |
| JP2008512527A5 (https=) | ||
| JP2022062153A5 (https=) | ||
| JP7158063B2 (ja) | グルカゴン保護剤及びその応用 | |
| Mabuchi et al. | Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum |